Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has officially disclosed its guidance for FY2026 consolidated revenue, targeting KRW 5.32T.
📊 [Key Disclosure Details & Financial Figures]
- Category: Forecast of Operating Performance (Fair Disclosure) based on Consolidated Financial Statements
- Target Period: January 1, 2026 – December 31, 2026 (FY2026)
- FY2026 Projected Revenue: KRW 5,320,000,000,000 (KRW 5.32T)
- Projected Operating Profit / Net Profit: Not stated
- Basis of Forecast: Market outlook and business plan
- Other Important Investment Matters:
- The FY2026 projected revenue represents the midpoint of the expected revenue growth range (+15% to +20% year-on-year).
- FY2025 revenue was KRW 4,557,000,000,000 (KRW 4.557T).
- The guidance is forward-looking based on business plans, and actual performance may differ due to changes in the business environment or market conditions.
- Prior Performance vs. Guidance Difference (FY2025):
- Projected Revenue: KRW 5,797,800,000,000 (KRW 5.798T / Guidance issued prior to spin-off, including Samsung Bioepis)
- Actual Revenue: KRW 4,557,000,000,000 (KRW 4.557T / Performance post-spin-off, excluding Samsung Bioepis)
- Discrepancy Rate: -21.4%
- Information Provision Details: Provided by IR Team to domestic and foreign investors on January 21, 2026 at 16:30 KST
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Actual FY2026 Revenue Performance Against Annual Guidance
This disclosure provides the company’s FY2026 revenue guidance based on its business plan, calculated using the midpoint of the expected +15% to +20% YoY growth range.
Monitoring quarterly revenue releases to check whether actual performance aligns with the annual guidance is crucial for understanding the company’s operational execution and growth trajectory.
Relevant progress can be verified in upcoming quarterly, half-year, and annual business reports and earnings performance disclosures.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
